Lipella Pharmaceuticals (LIPO) Stock Price, News & Analysis

Company Overview

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

Key Stats

• Today's Range: $2.50 to $2.56
• 50-Day Range: $2.15 to $3.19
• 52-Week Range: $1.97 to $12.00
• Volume: 6,899 shs
• Average Volume: 716,840 shs
• Market Capitalization: $6.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Lipella Pharmaceuticals Stock Analysis - MarketRank™

Lipella Pharmaceuticals scored higher than 49% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Lipella Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Lipella Pharmaceuticals is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lipella Pharmaceuticals is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lipella Pharmaceuticals has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.91% of the float of Lipella Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Lipella Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lipella Pharmaceuticals has recently decreased by 16.43%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lipella Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Lipella Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.91% of the float of Lipella Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Lipella Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lipella Pharmaceuticals has recently decreased by 16.43%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.22

News Sentiment

Lipella Pharmaceuticals has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Lipella Pharmaceuticals this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Lipella Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lipella Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.11% of the stock of Lipella Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

74.31% of the stock of Lipella Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LIPO Stock Analysis - Frequently Asked Questions

How have LIPO shares performed this year?

Lipella Pharmaceuticals' stock was trading at $3.05 at the beginning of the year. Since then, LIPO stock has decreased by 17.4% and is now trading at $2.52.
View the best growth stocks for 2025 here.

How were Lipella Pharmaceuticals' earnings last quarter?

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) issued its earnings results on Thursday, March, 27th. The company reported ($1.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.43) by $1.24. The business earned $0.17 million during the quarter. Lipella Pharmaceuticals had a negative net margin of 882.82% and a negative trailing twelve-month return on equity of 192.33%.

When did Lipella Pharmaceuticals' stock split?

Shares of Lipella Pharmaceuticals reverse split on the morning of Friday, November 8th 2024. The 1-8 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 7th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

When did Lipella Pharmaceuticals IPO?

Lipella Pharmaceuticals (LIPO) raised $7 million in an initial public offering (IPO) on Tuesday, December 20th 2022. The company issued 1,217,391 shares at a price of $5.75 per share.

How do I buy shares of Lipella Pharmaceuticals?

Shares of LIPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Lipella Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lipella Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), MSP Recovery (LIFW), MSP Recovery (LIFW), NVIDIA (NVDA), Processa Pharmaceuticals (PCSA), Energy Transfer (ET) and Labor Smart (LTNC).

Company Calendar

• Last Earnings: 3/27/2025
• Today: 5/01/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LIPO
• CIK: 1347242
• Web: lipella.com
• Phone: 412-901-0315
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($4.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,620,000.00
• Net Margins: -882.82%
• Pretax Margin: -882.61%
• Return on Equity: -192.33%
• Return on Assets: -154.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.97
• Quick Ratio: 2.97

Sales & Book Value

• Annual Sales: $536,357.00
• Price / Sales: 11.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.33 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 2,549,000
• Free Float: 821,000
• Market Cap: $6.42 million
• Optionable: Not Optionable
• Beta: 0.29